Synergy Pharmaceuticals (NASDAQ:SGYP) Receives News Sentiment Rating of 0.10

Press coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5057271677196 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) traded up 0.34% during midday trading on Friday, reaching $2.91. 3,905,872 shares of the company’s stock were exchanged. Synergy Pharmaceuticals has a 12-month low of $2.85 and a 12-month high of $7.15. The stock’s market capitalization is $654.62 million. The firm has a 50-day moving average of $3.93 and a 200-day moving average of $4.51.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.08. The firm had revenue of $2.31 million for the quarter, compared to analysts’ expectations of $1.98 million. During the same period last year, the firm earned ($0.23) earnings per share. Analysts anticipate that Synergy Pharmaceuticals will post ($1.09) EPS for the current fiscal year.

Several analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $9.00 price objective on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 10th. BTIG Research reaffirmed a “buy” rating and set a $11.00 price target on shares of Synergy Pharmaceuticals in a research report on Wednesday, May 31st. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Citigroup Inc. reaffirmed a “sell” rating and set a $3.70 price target on shares of Synergy Pharmaceuticals in a research report on Wednesday, June 28th. Finally, Canaccord Genuity set a $13.00 price target on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, July 31st. Four analysts have rated the stock with a sell rating and eight have issued a buy rating to the company. Synergy Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $10.07.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://rinconhillneighbors.org/2017/08/19/synergy-pharmaceuticals-nasdaqsgyp-earning-somewhat-positive-media-coverage-study-finds-updated-updated.html.

In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $3.77, for a total value of $99,101.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Insider Buying and Selling by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.